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Abstract
Background: Osteoarthritis (OA) is characterized by the degradation of articular cartilage, marked by the
breakdown of matrix proteins. Studies demonstrated the involvement of chemokines in this process, and some
may potentially serve as diagnostic markers and therapeutic targets; however, the underlying signal transductions
are not well understood.
Methods: We investigated the effects of the CC chemokine eotaxin-1 (CCL11) on the matrix metalloproteinase
(MMP) expression and secretion in the human chondrocyte cell line SW1353 and primary chondrocytes.
Results: Eotaxin-1 significantly induced MMP-3 mRNA expression in a dose-dependent manner. Inhibitors of
extracellular signal-regulated kinase (ERK) and p38 kinase were able to repress eotaxin-1-induced MMP-3 expression.
On the contrary, Rp-adenosine-3’,5’-cyclic monophosphorothioate (Rp-cAMPs), a competitive cAMP antagonist for
cAMP receptors, and H-89, a protein kinase A (PKA) inhibitor, markedly enhanced eotaxin-1-induced MMP-3
expression. These results suggest that MMP-3 expression is specifically mediated by the G protein-coupled eotaxin-
1 receptor activities. Interestingly, little amount of MMP-3 protein was detected in the cell lysates of eotaxin-1-
treated SW1353 cells, and most of MMP-3 protein was in the culture media. Furthermore we found that the
eotaxin-1-dependent MMP-3 protein secretion was regulated by phospholipase C (PLC)-protein kinase C (PKC)
cascade and c-Jun N-terminal kinase (JNK)/mitogen-activated protein (MAP) kinase pathways. These data indicate a
specific regulation of MMP-3 secretion also by eotaxin-1 receptor activities.
Conclusions: Eotaxin-1 not only induces MMP-3 gene expression but also promotes MMP-3 protein secretion
through G protein-coupled eotaxin-1 receptor activities. Chemokines, such as eotaxin-1, could be a potential
candidate in the diagnosis and treatment of arthritis.
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Background
Osteoarthritis (OA) is a chronic degenerative joint dis-
ease characterized by degradation of articular cartilage
and inflammation of the synovium [1,2]. Cartilage degra-
dation is mediated by matrix metalloproteinases
(MMPs), such as MMP-3 (stromelysin 1), which specifi-
cally cleave matrix proteins [3,4]. Chondrocytes, the
only cells found in cartilage, can produce interleukin
(IL)-1b that induces the expression of MMPs, aggreca-
nases, and other catabolic proteins [5,6]. Chondrocytes
in OA cartilage may continuously be exposed to
cytokines, chemokines and other catabolic factors at
high local concentrations; however, the underlying
effects and mechanisms are not well understood.
Chemokines are a family of small heparin binding
cytokines that are primarily involved in the recruitment
of leukocytes to the site of inflammation. Studies
revealed roles of chemokines and catabolic cytokines in
the inflammatory pathogenesis of OA [7,8]. Referring to
the juxtaposition of cysteine residues in the protein’s
amino terminus, four subfamilies can be distinguished
as C, CC, CXC, and CX3C [9]. In arthritic synovial tis-
sue, IL-1b induces the production of the CC chemo-
kines, such as monocyte chemoattractant protein 1
(MCP-1) and regulated upon activation of normal T cell
expression and secretion (RANTES), and promotes
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cytes respond to MCP-1 and RANTES by releasing
MMP-3 and N-acetyl-b-D-glucosaminidase, thus contri-
buting to cartilage matrix degradation [12]. Previously
we demonstrated that MCP-1, RANTES and another
chemokine, eotaxin-1 (CCL11), were overproduced in
OA joints [13]. The plasma concentrations of these che-
mokines were higher in OA patients than in normal
humans. The production of eotaxin-1 not only induces
expression of its own receptors, CCR3 and CCR5, on
the cell surface of chondrosarcomas, but also markedly
increases the expression of MMP-3 mRNA in chondro-
cytes. Recent study also demonstrated elevated level of
eotaxin-1 in the cells of rheumatoid arthritis (RA)
patients before disease onset [14].
Eotaxin-1 was first isolated from lung lavage fluid of
sensitized guinea pigs following allergen exposure [15].
The effects of eotaxin-1 are mediated by its binding to
G-protein-coupled CC chemokine receptors (CCRs)
[16,17]. Biochemical routes initiated by Ga subunit may
activate the main secondary message signal, adenylyl
cyclase-cAMP (AC-cAMP)-protein kinase A (PKA)
pathway, and subsequently activate mitogen-activated
protein (MAP) kinase pathway [18,19]. Activated MAP
kinase translocates to the nucleus and phosphorylates
transcription factors, thereby regulating gene expression
[20,21]. On the other hand, the activated Gbg subunits
may directly regulate phospholipase C (PLC)-protein
kinase C (PKC) pathway [18]. The effect of G protein
activation is mediated by both the AC-PKA and PLC-
PKC cascades [22].
PLC is a key point of the pathway that regulates protein
secretion. PLC has two major types including phosphati-
dylinositol specific phospholipase C (PI-PLC), and Phos-
phatidylcholine specific phospholipase C (PC-PLC). PI-
PLC digests glycosyl-phosphatidylinositol-anchored pro-
tein on the pancreatic zymogen granule membrane to
release the protein [23]. Acetylcholine activates insulin
granules in pancreatic b-cells through PC-PLC pathway
[24]. Furthermore, the effects on aldosterone secretion
are initiated by an increase in Ca
2+ influx through hor-
mone-operated Ca
2+ channels and G-protein- and PLC-
dependent hydrolysis of phosphoinositides, leading to the
generation of inositol 1,4,5 triphosphate (IP3) and diacyl-
glycerol (DAG) that induces intracellular Ca
2+ release
and PKC activation [25]. Ca
2+ influx and activation of
PKC have been known for many years to be key signals
of granule exocytosis and protein secretion. MMP-2
secretion from human ciliary muscle cells is regulated by
PKC-dependent pathway [26]. PKC also stimulates the
release of MMP-9 and tissue inhibitor of MMP1 in
human decidual cells [27].
Mitogen-activated protein (MAP) kinase pathways reg-
ulate cell growth, differentiation, gene expression,
protein synthesis and secretion. Three MAP kinase
pathways have been studied in detail: extracellular sig-
nal-regulated kinase (ERK) 1/2, c-Jun N-terminal kinase
(JNK), and p38 pathways. ERK 1/2 pathway is activated
by growth factors, G-protein coupled receptors and
phorbol esters, while the JNK and p38 MAP kinase
pathways respond to environmental factors and inflam-
matory cytokines [28]. MAP kinases are involved in
MMP mRNA production, and activated via different
pathways with different inducers in different tissues
[29]. IL-1 induces collagenase 3 (MMP-13) mRNA
expression through p38 and JNK pathways in chondro-
cytes [30]; however, in osteoblastic cells, MMP-13
mRNA expression is activated via ERK pathway [31].
In our previous study, we found that eotaxin-1 at a
high concentration induces MMP-3 mRNA production
in the chondrocytes. We now show that eotaxin-1-
induced MMP-3 expression is through cAMP/PKA and
MAP kinase pathways. Eotaxin-1 at a low concentration
is able to promote the MMP-3 release into the culture
media. The induction of MMP-3 secretion by eotaxin-1
is regulated by PLC/PKC and MAP kinase pathways.
Materials and methods
Materials
Eotaxin-1 and IL-1b were purchased from R&D systems
(Minneapolis, MN, USA). Inhibitors to ERK (PD98059),
MAPK-ERK-kinase (MEK) (U0126), p38 (SB203580),
JNK (SP600125), PI-PLC (U73122), PKA (KT5720), cal-
cium (BAPTA-AM), and PKC (chelery chloride) were
purchased from Tocris Bioscience (Bristol, UK). Inhibi-
tors to AC (2’,5’-dideoxyadenosine), PKA (H-89) and
cAMP (Rp-cAMP) were purchased from Biomol Inter-
national (Plymouth Meeting, PA, USA). Polyclonal anti-
body against MMP-3 was purchased from Oncogene
Science (Cambridge, MA, USA), and antibody of glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) was
from Zymed Laboratories (S. San Francisco, CA, USA).
Materials from human subjects were obtained and pro-
cessed under the regulation of TMU-Joint Institutional
Review Board.
Cell culture
Human SW1353 chondrosarcoma cells were purchased
from ATCC (Manassas, VA, USA). Cells were seeded at
a high density in Dulbecco’s modified Eagle’sm e d i u m
(DMEM) containing 10% fetal bovine serum (FBS)
(Gibco BRL), 100 U/ml penicillin and streptomycin, and
incubated with 5% CO2 at 37°C. Osteoarthritis knee car-
tilage was obtained from patients undergoing total joint
replacement surgery, and primary chondrocytes were
prepared as described previously [32,33]. Cartilage slices
were cut into pieces (2~3 mm
3), and chondrocytes were
released from articular cartilage by sequential enzymatic
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S t .L o u i s ,M O ,U S A )f o r1 5m i n ,0 . 2 5 %p r o n a s e( S i g m a
Chemical, St. Louis, MO, USA) for 30 min, then 2 mg/
ml type II collagenase (Sigma) for 12 h in DMEM con-
taining antibiotics (100 U/ml penicillin, 100 U/ml strep-
tomycin, and 2.5 mg/ml amphotericin B) at 37°C. After
filtration through a 100-meshnylon mesh and centrifu-
gation, chondrocyte residues were washed and seeded at
a high density in DMEM supplemented with 10% FBS
and antibiotics, and incubated with 5% CO2 at 37°C.
Reverse-Transcription Polymerase Chain Reaction (RT-
PCR)
Total RNA was isolated from cultured cells, and RT-
PCR was performed as described previously [13]. In
brief, complementary DNA was synthesized in a 25-μl
reaction mixture containing 5 μg of total RNA, 2.5 mM
of each dNTP, 1 mM of random hexamer primers, and
10 U of M-MLV reverse transcriptase (Epicentre, Madi-
son, WI), by incubation at 37°C for 90 min. The result-
ing cDNA (2 μl) was subjected to PCR using Taq DNA
polymerase (Epicentre) and specific primers for MMP-3
and GAPDH. MMP-3 forward primer: 5’-CCTCTGATG
GCCCAGAATTGA-3’; reverse primer: 5’-GAAATTGG
CCACTCCCTGGGT-3’ and GAPDH forward primer:
5’-CCACCCCATGGCAAATTCCATGGCA-3’; reverse
primer 5’-TCTAGACGGCAGGTCAGGTCCACC-3’.
For MMP-3, the PCR protocol was 35 cycles at 94°C for
1 min, 56°C for 1 min, and 72°C for 1 min. In each
experiment, amplification of cDNA for the housekeeping
gene, GAPDH, was used as an internal standard. PCR
products were analyzed on 1.5% agarose gels.
Western blot analysis and determination of MMP-3
Proteins were separated in SDS-PAGE according to stan-
dard protocol and transferred onto PVDF-nylon mem-
branes (Millipore). The membrane was blocked with 5%
non-fat milk in TBST (10 mM Tris-HCl, pH7.5, 150 mM
NaCl, and 0.1% Tween-20) at room temperature for 1 h.
After a brief wash, the membrane was incubated with pri-
mary antibody diluted in TBST for 60-90 min. The mem-
brane was then washed 3 times with TBST and probed
with horseradish peroxidase-conjugated secondary anti-
body (1:3000, Santa Cruz Biotechnology, Santa Cruz, CA)
for 30-60 min. After extensive washes, specific signals
were visualized by an enhanced chemiluminescence
(ECL) system (Pierce, Rockford, IL) according to the
manufacture’s instruction. Western bands were digita-
lized and quantified by UN-SCAN-IT gel 6.1 software
(Silk Scientific Inc., Orem, UT, USA).
IP3 detection
Cells were suspended in the phosphate-buffered saline
(PBS), and were incubated with 0.2 volume of ice-cold
20% trichloroacetic acid on ice for 20 min. The protein
sediment was precipitated by centrifugation at 2000 × g
for 15 min at 4°C, and the supernatant was adjusted
with ice-cold 10 M KOH to pH 7.5. The KClO4 sedi-
ment was removed by centrifugation at 2000 × g for 15
min at 4°C. The Ins(1,4,5)P3 level in supernatant was
determined using Inositol-1,4,5-Trisphosphate [
3H]
Radioreceptor Assay Kit (Amersham Biosciences).
Statistical analysis
The mean and standard deviation (SD) were used to
illustrate the results from at least three data sets of each
experiment. Statistical significance (p <0 . 0 5 )w a s
assessed using Student’s test or one-way analysis of var-
iance, followed by a post hoc analysis using Dunnett’s
test when appropriate.
Results
Eotaxin-1 induces MMP-3 gene expression and protein
secretion in human chondrocytes
In our previous study, we found that eotaxin-1 is over-
expressed in OA patients [13]. Eotaxin-1 induces MMP-
3 mRNA expression in human chondrocytes. Similarly
in the present study, we demonstrated that MMP-3
expression in SW1353 chondrosarcoma cells and pri-
mary chondrocytes was obviously induced by eotaxin-1
at 30 and 10 ng/ml, respectively (Figure 1A and 1B). It
is notable that treatment with eotaxin-1 alone was able
to induce MMP-3 expression in both primary chondro-
cytes and a chondrosarcoma cell line. However, we trea-
ted cells with IL-1b in addition to eotaxin-1 in most of
further experiments to magnify the overall effects.
In order to check the eotaxin-1-induced MMP-3 pro-
tein levels in chondrosarcoma cells, we performed Wes-
tern blotting using cell lysates and culture media. With
only IL-1b treatment (1 ng/ml) for 24 h, MMP-3 protein
was present in both the cytosol and culture media. Sur-
prisingly, after treating the cells with 100 ng/ml eotaxin-
1a l o n gw i t hI L - 1 b, MMP-3 protein levels were not
detected in cell lysates at the time points from 4 h to 24
h, and only found in the culture media (Figure 2A). The
levels of MMP-3 protein in culture media increased
with time.
To clarify the effect of eotaxin-1 on MMP-3 secretion,
we used actinomycin D (ActD) to eliminate the effects
from MMP-3 expression. ActD is an inhibitor of tran-
scription, and has been used, at concentrations ranging
from 1 to 10 μg/ml, to inhibit gene expression in
human chondrocytes [34,35]. In the presence of ActD (5
μg/ml or 4 μM), IL-1b-induced MMP-3 protein level in
culture media was reduced, especially in primary cell
cultures, suggesting efficient suppression of MMP-3
gene by ActD (Figure 2B). Indeed, eotaxin-1 at moderate
concentrations still significantly promoted the MMP-3
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inhibited. Since the inhibition of transcription of MMP-
3 did not block the effect of eotaxin-1 on promoting
MMP-3 levels in culture media, the phenomena may be
attributed to the eotaxin-1-enhanced secretion of MMP-
3 protein. It was noted that primary cells were less
responsive to eotaxin-1 than SW1353. Perhaps the pri-
mary chondrocytes from OA patients were customized
to high eotaxin-1 concentrations.
It is plausible that eotaxin-1 not only induced MMP-3
gene expression but also promoted the protein secretion
into culture media from human chondrocytes.
RANTES and MCP-1 induce MMP-3 gene expression but
not protein secretion
Our earlier results also indicated high plasma concentra-
tions of the other two chemokines, RANTES and MCP-
1a in OA patients [13]. Therefore we checked their
effects on MMP-3 mRNA expression, and protein levels
in cells and media. As shown in Figure 3, both RANTES
and MCP-1 at moderate concentrations increased the
level of MMP-3 mRNA (Figure 3A and 3B, upper
panels). Similar to eotaxin-1 and consistent with the
previous report, RANTES and MCP-1 are involved in
MMP-3 gene regulation. However, greater protein levels
of MMP-3 were found in cell lysates than in culture
media in both experiments (Figure 3A and 3B, lower
panels), suggesting that RANTES and MCP-1 are not
involved in regulation of MMP-3 secretion.
MAP kinases are involved in eotaxin-1-induced MMP-3
gene expression and protein secretion
To investigate the pathways that involve eotaxin-1 and
MMP-3, we used inhibitors of ERK, p38, and JNK MAP
kinases. The eotaxin-1-induced mRNA levels of MMP-3
were apparently decreased by the inhibitors of ERK
SW1353 cells 
C    IL-1β    3      10      30    100 
Eotaxin-1(ng/ml)  
- MMP-3 
- GAPDH
B 
C   IL-1β    3      10      30    100 
Eotaxin-1 (ng/ml) 
- MMP-3 
- GAPDH 
Primary chondrocytes 
A  
Figure 1 Effect of eotaxin-1 on the MMP-3 gene expression in human chondrocytes. Primary human chondrocytes (A) and SW1353
chondrosarcoma cells (B) were incubated with various concentrations of Eotaxin-1 or IL-1b (1 ng/ml) for 6 h, and MMP-3 mRNA expression was
detected by RT-PCR. These experiments were performed three times.
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Figure 2 Effect of eotaxin-1 on the MMP-3 protein secretion in human chondrocytes. Human SW1353 chondrosarcoma cells and primary
chondrocytes were cultured and treated in different conditions. MMP-3 protein levels were analyzed by Western blotting, and quantified. All
values were normalized to the one without eotaxin-1. (A) SW1353 cells were incubated with 1 ng/ml IL-1b and 100 ng/ml eotaxin-1 for various
time periods or only IL-1b for 24 h, and MMP-3 protein expressed in cells (c.MMP-3) and culture media (m.MMP-3) were analyzed and quantified.
(B) SW1353 or primary cells were incubated with IL-1b (1 ng/ml) for 4 h followed by actinomycin D (5 μg/ml) for 1 h. The medium was then
refreshed, and the cells were treated with various concentrations of eotaxin-1 for 2 h. MMP-3 protein in culture medium was determined. The
values are the mean of at least three assays. * p < 0.05.
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Figure 3 Effects of other CC chemokines on the MMP-3 gene expression and protein secretion in human chondrosarcoma cells.
SW1353 cells were incubated with 1 ng/ml IL-1b, or various concentrations of RANTES (A) or MCP-1 (B) for 24 h. MMP-3 mRNA levels were
analyzed by RT-PCR, and the protein expressed in cells (c.MMP-3) and secreted in media (m.MMP-3) were assayed by Western blotting. These
experiments were performed three times.
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Page 6 of 13(PD98059) at 10 μM and p38 (SB203580) at 3 μM, but
not JNK (SP600125) at 20 μM( F i g u r e4 A ,Ba n d4 C ) .
This suggests the involvement of both ERK and p38 in
the regulation of eotaxin-1 signaling through MMP-3
expression in chondrocytes.
The effects of these inhibitors on MMP-3 secretion in
the cells were then examined. The ERK and P38 inhibi-
tor concentrations that are higher than those effective in
reducing MMP-3 gene expression did not inhibit
eotaxin-1-induced MMP-3 protein secretion (Figure
4D). In contrast, a low concentration of JNK inhibitor
significantly reduced MMP-3 protein secretion which
was induced by eotaxin-1 in a dose-dependent manner.
This indicates a role for JNK in the pathway of eotaxin-
1-induced MMP-3 protein secretion in chondrocytes.
AC/PKA is inhibitory in eotaxin-1-induced MMP-3 gene
expression
Rp-cAMP inhibits cAMP on the activation of down-
s t r e a mp r o t e i n s ,s u c ha sP K A .C h o n d r o s a r c o m ac e l l s
were pretreated with Rp-cAMP prior to the treatment
with eotaxin-1. Interestingly Rp-cAMP increased the
level of eotaxin-1-induced MMP-3 mRNA at moderate
concentrations (Figure 5A). Consistent with the finding,
PKA inhibitor also increased the level of MMP-3 mRNA
at low concentrations. These results indicate that AC/
PKA is inhibitory in eotaxin-1 signal transduction by
down-regulating MMP-3 expression. Eotaxin-1 may
indeed activate MAP kinases by inhibiting AC/PKA
activities.
PI-PLC is involved in eotaxin-1-induced MMP-3 protein
secretion
IP3 is a catalytic product of PLC, and IP3 level indicates
the activity of PI-PLC pathways. As shown in Figure 6A,
IP3 levels were increased by eotaxin-1 in a dose-depen-
dent manner. Eotaxin-1 may activate phospholipase C,
and increase the production of IP3 at a concentration
lower than 100 ng/ml. Cells were further tested by treat-
ing with inhibitors of PLC (U73122), calcium (BAPTA-
AM), PKC (Chelery chloride), or adenylate cyclase (ACi)
prior to the treatment with eotaxin-1 (10 ng/ml). The
levels of secreted MMP-3 protein were decreased in a
dose-dependent manner by inhibitors of PLC, calcium
and PKC, but not adenylate cyclase (Figure 6B). These
data indicate that both PLC/PKC pathway and the cal-
cium influx may be involved in eotaxin-1-induced
MMP-3 protein secretion.
Discussion
Chondrocytes are major cells of cartilage in joints, and
are implicated in the pathology of OA which is a multi-
factorial disease. One of the factors is imbalance of
MMPs. In our previous study, MMP-3 is highly
correlative with OA by increasing collagen degradation
in the cartilage matrix [13]. In the plasma and synovial
fluid of OA patient, two catabolic cytokines, IL-1b and
TNF-a, and several chemokines including eotaxin-1
were highly expressed. The release of MMP-3 from
chondrocytes and synoviocytes in response to the stimu-
lations may play a major role in the progressive cartilage
disruption in OA patients. In this study, the signal
transduction pathways regulating MMP-3 gene expres-
sion and protein secretion in response to eotaxin-1 in
human chondrocytes were investigated. The results
demonstrated that the three examined chemokines
(RANTES, MCP-1, and eotaxin-1) were able to induce
t h ee x p r e s s i o no fM M P - 3 ;h o w e v e r ,o n l ye o t a x i n - 1w a s
able to promote the secretion of MMP-3 from the cells.
Further experiments demonstrated that eotaxin-1 may
inhibit cAMP/PKA, and activate ERK and p38 MAP
kinases to induce MMP-3 expression (Figure 7A).
Meanwhile eotaxin-1 signaling may also be mediated by
PLC-PKC cascade, and JNK MAP kinase pathway to
promote MMP-3 secretion (Figure 7B).
The eotaxin-1 receptor CCR3 expressed on SW1353
chondrosarcoma cells belongs to the family of G pro-
tein-coupled receptors. The effects of eotaxin-1 were
sensitive to pertussis toxin. Eotaxin-1 stimulation results
in a rapid decrease of cAMP levels indicating association
of the eotaxin-1 receptors with Gai proteins. Addition of
cAMP inhibitor (Rp-cAMP) enhanced the effects of
eotaxin-1-induced transcription (Figure 5A). This find-
ing supports that cAMP plays a central role in eotaxin-
1-induced MMP-3 expression. A key target for cAMP is
PKA. The PKA inhibitor also increased the effects of
eotaxin-1 by inducing MMP-3 transcription in chondro-
s a r c o m ac e l l s( F i g u r e5 B ) .T hese results indicate that
AC/PKA negatively modulates transcription of MMP-3
in chondrosarcoma cells.
MEK lies at the key point of a signaling network that
controls cell proliferation, neoplastic transformation,
and differentiation. Many of these effects are transmitted
via the MAP kinase pathway. The inhibitors of ERK and
p38 MAP kinases decreased the mRNA level of MMP-3
(Figure 4A and 4B). It implicates that these MAP
kinases are involved in MMP-3 transcription induced by
eotaxin-1. Similar effect by other chemokines in human
articular chondrocytes was also reported recently [36].
T h ec r o s s - t a l ko fP K Aa n dM A Pk i n a s ep a t h w a y sw a s
discussed in previous studies [19,37]. MAP kinases are
regulated by cAMP/PKA pathway, and PKA also cross-
talks with Raf-1, indicating that MAPK could control
transcription through AP-1 and NF-B. These observa-
tions conclude direct relevance of eotaxin-1 to MMP-3
expression in osteoarthritis.
Interestingly, the JNK inhibitor, SP600125, did not
inhibit eotaxin-1-induced MMP-3 expression at
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Figure 4 Involvement of MAP kinases in eotaxin-1-induced MMP-3 gene expression and protein secretion in human chondrosarcoma
cells. SW1353 cell were pretreated for 1 h with inhibitors as follows: ERK inhibitor PD98059 at 1, 5 and 10 μM (A), p38 inhibitor SB203580 at 0.1,
1 and 3 μM (B), and JNK inhibitor SP600125 at 10 and 20 μM (C). The cells were then treated with eotaxin-1 (100 ng/ml) or IL-1b (1 ng/ml) for 6
h. MMP-3 mRNA expression was assayed by RT-PCR. (D) MMP-3 protein secretion of the cells treated with the inhibitors was also analyzed by
Western blotting and quantified. Concentrations of the inhibitors used from low to high: 10 and 20 μM PD98059, 5 and 10 μM SB203580, 2.5
and 5 μM SP600125. These experiments were performed at least three times. The values in the plot were the mean of at least three assays.
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Page 8 of 13relatively high concentrations (Figure 4C). Similar effects
of different stimuli on MAP kinase pathways to MMP
expression in chondrocytes were also reported in recent
studies. Leptin, produced by joint white adipose tissue,
induced MMP-1 and MMP-13 expression in chondro-
cytes [38]. Inhibitors of ERK and p38 pathways signifi-
cantly reduced those MMPs expression; however, JNK
inhibition had no effect on leptin-induced MMP-13
expression. Mechanical stress-induced MMP-13 was
down-regulated by p38 inhibitor SB203580 but not by
the ERK inhibitor U0126, or the JNK inhibitor JNK inhi-
bitor II in another report in another report [39]. The
JNK seemed to distinguish itself from other MAP
kinases in regulating MMP activities in chondrocytes.
Indeed, our data suggested an important pathway for
eotaxin-1 to stimulate MMP secretion via JNK MAP
kinase (Figure 4D and 7B).
Since the Gi protein is one of the subunits composed
of eotaxin-1 receptor, CCR3, it is believed that Gi-
coupled receptors are primarily mediated by bg-subunit
complex to activate MAP kinase. One mechanism
appears to be PI3K dependent. Signaling from PI3K to
MAP kinase pathway requires a tyrosine kinase, indicat-
ing that the GPCR is involved. It is known that binding
of eotaxin-1 to CCR3 activates not only Gai subunit but
also Gbg that potentially related to protein secretion
[40]. PLC is the key molecule of regulating protein
secretion pathways. Stimulation of chemokine receptors
rapidly activates PI-specific PLC, which leads to IP3 for-
mation and a transient rise in the concentration of
A 
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 MMP-3 
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Figure 5 Involvement of AC/PKA in eotaxin-1-induced MMP-3 gene expression in human chondrosarcoma cells. SW1353 cell were
pretreated with various concentrations of cAMP inhibitor Rp-cAMP (A) or PKA inhibitor H-89 (B) for 1 h, and then treated with eotaxin-1(100 ng/
ml) or IL-1b (1 ng/ml) for 6 h. MMP-3 mRNA expression was assayed by RT-PCR. These experiments were performed three times.
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Page 9 of 13intracellular free calcium. Our data show that inhibition
of PLC by U73122 abolishes eotaxin-1-induced MMP-3
release (Figure 6B). This is evident that PI/PLC is
involved in the regulation of MMP-3 secretion pathway
induced by eotaxin-1. There were studies showing the
involvement of PLC in gene regulation of MMP-3 in
fibroblasts [41] and other MMPs in chondrosarcoma
cells [42]. It is possible that PLC is also involved in the
eotaxin-1-induced MMP-3 gene expression. Further
experiments may be performed in future studies.
Activated PLC has been reported to stimulate IP3, cal-
cium influx, and PKC in a number of cell types. The sti-
mulation of neutrophils by receptor-binding ligands can
activate PLC with the formation of IP3 which releases
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Figure 6 Involvement of PI-PLC in eotaxin-1-induced MMP-3 secretion in human chondrosarcoma cells. (A) SW1353 cells were treated
with various concentrations of eotaxin-1 for 30 min, and determined IP3 level by IP3 [
3H] radioreceptor assay. (B) SW1353 cell were treated for 4
h with IL-1b (1 ng/ml) followed by 1 h with actinomycin D (5 μg/ml) and various inhibitors as follows: PI-PLC inhibitor U73122 (5, 10 or 20 μM),
calcium inhibitor Bapta-AM (Bapta; 5, 10 or 20 μM), PKC inhibitor chelery chloride (Chelery; 0.5, 1 or 2 μM), or adenylate cyclase inhibitor 2’,5’-
dideoxyadenosine (ACi; 100, 250 and 500 μM). The cells were then treated with eotaxin-1 (100 ng/ml) for 4 h. MMP-3 protein secreted in culture
media was determined by Western blotting and quantified. The values in the plots were the mean of at least three assays. * p < 0.05.
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2+ from intracellular storage, and DAG which acti-
vates PKC [43]. Indeed our results show that eotaxin-1
stimulation resulted in a rapid increase of IP3 levels,
and inhibition of calcium and PKC decreases the MMP-
3 protein secretion induced by eotaxin-1 (Figure 6). The
MMP-3 protein secretion induced by eotaxin-1 is,
thereby, calcium dependent, and associated with Gbg
proteins and PLC. Moreover, eotaxin-1-activated PLC
Fig. 7  A 
B 
-1.
Figure 7 Models of eotaxin-1 function on MMP-1 gene expression and protein secretion in human chondrocytes. (A) Eotaxin-1 binds G
protein-coupled CCRs, such as CCR3, and induces MMP-3 expression through cAMP/PKA inhibition and MAP kinase activation. (B) Eotaxin-1 at
low concentrations is able to promote MMP-3 release from the cells by activating PLC/PKC and MAP kinase pathways.
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Page 11 of 13not only induced intracellular calcium release but also
activated PKC. Activation of PKC by eotaxin-1 suggests
a potential role for PKC-induced MMPs in the mechan-
isms responsible for membrane rupture. Recent studies
showed that activation of PKC is involved in the induc-
tion of MMP secretion by cytokines in smooth muscle
cells [44]. Our data clearly show that PKC inhibitor sig-
nificantly decreased the secretion of MMP-3 in a dose-
dependent manner. PKC is, therefore, involved in
eotaxin-1-induced MMP-3 secretion pathway.
Conclusions
Human chondrocytes respond to the stimulation of
eotaxin-1 by up-regulating MMP-3 expression and
secretion, which may be mediated by Gai and Gbg sub-
units of G-coupled protein receptor, respectively. High
concentrations of eotaxin-1 inactivate cAMP/PKA, and
spark ERK and p38 MAP kinases to regulate MMP-3
transcription. Yet, at low concentrations, eotaxin-1 acti-
vates PI3K and JNK MAP kinase to stimulate secretion
of MMP-3, which plays an important role in OA patho-
genesis. Critically, eotaxin-1 not only induces MMP-3
transcription but also enhances MMP-3 secretion. Our
results shed light on key roles of eotaxin-1 in cartilage
destruction in OA, and suggest a potential diagnostic
and therapeutic target for this disease.
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